Drug Profile
Research programme: cancer therapeutics - Novelix
Alternative Names: NVX-144; NVX-188Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator University of Southern California
- Class Small molecules
- Mechanism of Action Apoptosis stimulants; Integrin alphaVbeta3 antagonists; Interleukin 24 stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA
- 04 Sep 2009 Preclinical development is ongoing in USA
- 19 Dec 2005 Preclinical trials in Cancer in USA (unspecified route)